A Study to Investigate Pharmacokinetics and Safety of Rupatadine (10 mg) and Its Active Metabolites in Participants With Renal Impairment Compared to Matched Control Participants With Normal Renal Function
Latest Information Update: 02 Jun 2025
At a glance
- Drugs Rupatadine (Primary)
- Indications Renal impairment
- Focus Pharmacokinetics
Most Recent Events
- 28 May 2025 Planned End Date changed from 1 Dec 2024 to 1 Jul 2025.
- 28 May 2025 Planned primary completion date changed from 1 Dec 2024 to 1 Jul 2025.
- 03 Dec 2024 New trial record